Objective: To assess the cost-effectiveness of two COVID-19 oral antivirals (COAVs) Paxlovid and Molnupiravir compared to the standard of care, in Ghana, Rwanda and Zambia. Methods: We modelled costs (2022 US$) and health outcomes in the acute phase of the COVID-19 disease from a public payer9s perspective in three unvaccinated target populations (1) patients aged 65 years and above (elderly); (2) adult patients with at least one other underlying risk factors for disease severity; and (3) all adult patients. In addition, we conducted a series of sensitivity and scenario analyses. Results: In elderly patients, Paxlovid was less costly and more effective (i.e., dominated) than standard of care in all three study countries. Molnupiravir dominated standard of care in Rwanda and Zambia and an incremental cost-effectiveness ratio (ICER) was estimated at US$1023.58 per disability-adjusted life year (DALY) averted in Ghana. In adults with other underlying risk factors, Paxlovid dominated in Rwanda and Zambia while Molnupiravir dominated in Rwanda. Neither Paxlovid nor Molnupiravir were cost-effective in the all-adult group in any country context. Incremental net monetary benefit for Paxlovid was consistently higher than for Molnupiravir. In COVID-19 vaccinated patients, Paxlovid was cost-effective for elderly patients in Zambia and Rwanda but not in Ghana. Key determinants of cost-effectiveness were COAV price, likelihood of early treatment initiation, and hospitalization rates. Conclusion: In African settings similar to Zambia, Ghana or Rwanda, COAVs could be cost-effective in populations who are unvaccinated, and at high risk of progression to severe COVID-19. More evidence is needed to determine cost-effectiveness for patients that are unvaccinated but have previously been infected with COVID-19 and may have developed some immune protection.
Background: The emergence of the COVID-19 vaccination has been critical in changing the course of the COVID-19 pandemic, with estimates suggesting vaccinations have prevented millions of deaths worldwide. To ensure protection remains high in groups at high-risk, booster vaccinations in the UK have been targeted based on age and clinical vulnerabilities. We sought to identify adults at increased risk of COVID-19 death, and compared to non-COVID-19 risk, despite having received a booster dose as part of the 2022 autumn vaccination campaign in England. Methods: We undertook a national retrospective cohort study using data from the 2021 Census linked to electronic health records. We fitted cause-specific Cox regression to examine the association between a range of health conditions and the risk of COVID-19 death and all-other-cause death for adults aged 50-100-years in England vaccinated with a booster in autumn 2022. Findings: Our total population was 14,644,570 people; there were 6,800 COVID-19 deaths (52. and 150,075 non-COVID-19 deaths. Having learning disabilities or Down Syndrome (hazard ratio=5.07;conficence interval=3.69-6.98), pulmonary hypertension or fibrosis(2.88;2.43-3.40), motor neuron disease, multiple sclerosis, myasthenia or Huntington9s disease (2.94, 1.82-4.74), cancer of blood and bone marrow (3.11;2.72-3.56), Parkinson9s disease (2.74;2.34-3.20), lung or oral cancer (2.57;2.04 to 3.24), dementia (2.64;2.46 to 2.83) or liver cirrhosis (2.65;1.95 to 3.59) was associated with an increased risk of COVID-19 death. Individuals with cancer of the blood or bone marrow, chronic kidney disease, cystic fibrosis, pulmonary hypotension or fibrosis, or rheumatoid arthritis or systemic lupus erythematosus had a significantly higher risk of COVID-19 death relative to other causes of death compared with individuals who did not have diagnoses of these comorbidities. Interpretation: We identify groups who are at increased risk of COVID-19 death relative to non-COVID-19 deaths. Vulnerable groups should continue to be prioritised for COVID-19 booster doses to minimise the risk of COVID-19 deaths.
Background Projects such as the European Covid-19 Forecast Hub publish forecasts on the national level for new deaths, new cases, and hospital admissions, but not direct measurements of hospital strain like critical care bed occupancy at the sub-national level, which is of particular interest to health professionals for planning purposes. Methods We present a sub-national French framework for forecasting hospital strain based on a non-Markovian compartmental model, its associated online visualisation tool and a retrospective evaluation of the real-time forecasts it provided from January to December 2021 by comparing to three standard statistical forecasting methods (auto-regression, exponential smoothing, and ARIMA). Results For anticipating risk of critical care unit overload, our model performed worse than pure statistical methods at the one- and two-week horizons, but had better point forecasts at the four-week horizon for 8 of the 13 regions considered. Our model also suffered from over-confidence with respect to its prediction intervals. Conclusions Online visualisation tools and consideration of how metrics can be affected by distortion from non-pharmaceutical government interventions are essential in the assessment of forecasting models for hospital strain.
During the early stages of the Covid-19 pandemic in South Africa, one of many challenges included availability of control material proficiency testing programs. Control material utilising live SARS-CoV-2 or RNA extracted from cell culture was either biohazardous and costly, particularly in resource limited settings. Here, we report the development and application of a non-infectious SARS-CoV-2 biomimetic Mycobacterium smegmatis strain that mimics a positive result in the GeneXpert SARS-CoV-2 Xpert Xpress cartridge. Nucleotide sequences located in genes encoding the RNA-dependent RNA polymerase, the nucleocapsid and the envelope proteins were used. The resulting biomimetic was prepared as a Quality Control specimen and distributed to laboratories in South Africa for validation prior to testing of clinical specimens. Between April 2020 and December 2020, a total of 151 instruments were validated to bring Covid-19 mass testing online. These instruments capacitated the country to perform tests in 2532 modules. False negative or false positive findings reflected issues such as workflow/technician error or other related technical issues. This non-infectious, easily scalable control material became available within two months after the start of the pandemic in South Africa and represents a useful approach to consider for other diseases and future pandemics.
Role of Ivermectin and Colchicine in Treatment of COVID-19: Randomized Controlled Clinical Trial - Condition: COVID-19
Interventions: Drug: Ivermectin Tablets; Drug: Colchicine 0.5 MG; Drug: Standared managment
Sponsor: Ain Shams University
Completed
COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists - Condition: COVID-19
Interventions: Behavioral: Standard implementation webinar and online training; Behavioral: Virtual facilitation
Sponsors: University of North Carolina, Chapel Hill; University of Arkansas; University of South Carolina; National Institute on Minority Health and Health Disparities (NIMHD)
Not yet recruiting
LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients - Conditions: COVID-19; Hospitalized COVID-19 Patients
Interventions: Drug: Lopinavir / Ritonavir; Drug: Remdesivir (RDV); Drug: Tocilizumab; Other: Corticosteroid Therapy-enhanced Standard Care (CTSC)
Sponsors: Lebanese University; Hospital Saydet Zgharta University Medical Center
Recruiting
Comprehensive Imaging Exam of Convalesced COVID-19 Patients - Conditions: COVID-19; COVID Long-Haul
Interventions: Other: Magnetic Resonance Imaging; Other: Ultra-High Resolution Computed Tomography (CT) Scan
Sponsors: Johns Hopkins University; Canon Medical Systems, USA
Enrolling by invitation
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study) - Conditions: COVID-19 Pandemic; COVID-19 Vaccines
Interventions: Biological: Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg; Biological: CoronaVac Biofarma COVID-1 9 Vaccine 3 µg
Sponsors: Dr. Soetomo General Hospital; Indonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, Indonesia
Recruiting
Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults - Condition: COVID-19
Interventions: Biological: SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection; Biological: SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Not yet recruiting
The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002 - Condition: COVID-19
Interventions: Biological: LYB002V14; Biological: LYB002V14A; Biological: LYB002CA
Sponsors: Guangzhou Patronus Biotech Co., Ltd.; Yantai Patronus Biotech Co., Ltd.; Affiliated Hospital of North Sichuan Medical College
Active, not recruiting
Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent and Bivalent SARS-CoV-2 rS Vaccines in Adults ≥ 50 Years - Condition: COVID-19
Interventions: Biological: NVX-CoV2540 (5, 10, 25 μg); Biological: NVX-CoV2373 (5 μg); Biological: Bivalent BA.4/5 Omicron subvariant
Sponsor: Novavax
Not yet recruiting
Evaluating the Efficacy of Remdesivir for Long COVID Following a Confirmed COVID-19 Infection. - Conditions: SARS-CoV-2 Infection; COVID-19
Intervention: Drug: Remdesivir
Sponsors: University of Derby; University of Exeter; Peninsula Clinical Trials Unit; University Hospitals of Derby and Burton NHS Foundation Trust
Not yet recruiting
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001 - Conditions: COVID-19; Vaccine Reaction
Interventions: Biological: LYB001; Biological: CoronaVac
Sponsors: Guangzhou Patronus Biotech Co., Ltd.; Yantai Patronus Biotech Co., Ltd.; Affiliated Hospital of North Sichuan Medical College
Active, not recruiting
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome - Condition: Post-Acute COVID-19 Syndrome
Interventions: Drug: Placebo; Drug: Anakinra 149 MG/ML Prefilled Syringe [Kineret]
Sponsor: Hellenic Institute for the Study of Sepsis
Not yet recruiting
The Effect of Smart Sensor Combined With APP for Individualized Precise Exercise Training in Long Covid-19 - Conditions: Coronavirus Disease; COVID-19; Long Covid-19; Telerehabilitation
Interventions: Device: KNEESUP smart knee assistive device + KNEESUP care APP; Device: KNEESUP care APP; Behavioral: Healthy consulation
Sponsor: Shang-Lin Chiang
Recruiting
Effects of Music Combined With Sports Games on Alleviating Psychological Stress, Anxiety and Mental Energy Among Adolescents During COVID-19 Pandemic in Lanzhou Gansu Province China - Conditions: Stress; Anxiety and Fear
Interventions: Behavioral: Music intervention only; Behavioral: Sports games intervention only; Behavioral: Music and sports games intervention
Sponsor: Wu Jiarun
Completed
Pandemic-Proofing Simulation-based Education - Condition: COVID 19
Interventions: Device: VR Headset; Other: Traditional Theatre-based simulation
Sponsors: Ottawa Hospital Research Institute; Sunnybrook Research Institute
Not yet recruiting
Study on the Remote Diagnosis and Treatment Strategy of New-onset Insomnia Under the COVID-19 Epidemic - Conditions: Insomnia; CBT; Depression; Anxiety
Intervention: Device: CBTI online programe
Sponsor: Nanfang Hospital, Southern Medical University
Enrolling by invitation
Conformational response to ligand binding of TMPRSS2, a protease involved in SARS-CoV-2 infection: Insights through computational modeling - Thanks to the considerable research which has been undertaken in the last few years to improve our understanding of the biology and mechanism of action of SARS-CoV-2, we know how the virus uses its surface spike protein to infect host cells. The transmembrane prosthesis, serine 2 (TMPRSS2) protein, located on the surface of human cells, recognizes the cleavage site in the spike protein, leading to the release of the fusion peptide and entry of the virus into the host cells. Because of its role,…
Respiratory infections in children and adolescents in Germany during the COVID-19 pandemic - CONCLUSIONS: While the measures taken were effective in inhibiting the number of respiratory infections for almost 1.5 years, moderately frequent but rather mild COVID-19 cases occurred when measures were lifted. When Omicron emerged in 2022 COVID-19 became moderately frequent but led predominantly to mild illnesses. For RSV and influenza, the measures resulted in changes in their annual timing and intensity.
Maternal prenatal attachment during the COVID-19 pandemic: exploring the roles of pregnancy-related anxiety, risk perception, and well-being - Pregnant women have faced novel physical and mental health risks during the pandemic. This situation is remarkable because a parent’s emotional bond with their unborn baby (also known as prenatal attachment) is related to the parent’s mental state. Prenatal attachment helps parents psychologically prepare for the transition into parenthood. Moreover, it plays a pivotal role in the future parentchild relationship and psychosocial development of the baby. Based on the available literature, the…
Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants - SARS-CoV-2 poses an unprecedented threat to the world as the causative agent of the COVID-19 pandemic. Among a handful of therapeutics developed for the prevention and treatment of SARS-CoV-2 infection, ensitrelvir is the first noncovalent and nonpeptide oral inhibitor targeting the main protease (M^(pro)) of SARS-CoV-2, which recently received emergency regulatory approval in Japan. Here we determined a 1.8-Å structure of M^(pro) in complex with ensitrelvir, which revealed that ensitrelvir…
Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice - As the COVID-19 pandemic transitions into endemicity, seasonal boosters are a plausible reality across the globe. We hypothesize that intranasal vaccines can provide better protection against asymptomatic infections and more transmissible variants of SARS-CoV-2. To formulate a protective intranasal vaccine, we utilized a VLP-based platform. Hepatitis B surface antigen-based virus like particles (VLP) linked with receptor binding domain (RBD) antigen were paired with the TLR4-based agonist…
Synthesis and characterization of n-phosphonium chitosan and its virucidal activity evaluation against coronavirus - Despite the worldwide vaccination effort against COVID-19, the demand for biocidal materials has increased. One promising solution is the chemical modification of polysaccharides, such as chitosan, which can provide antiviral activity through the insertion of cationic terminals. In this study, chitosan was modified with (4-carboxybutyl) triphenylphosphonium bromide to create N-phosphonium chitosan (NPCS), a quaternized derivative. The resulting NPCS samples with three degrees of substitution…
Identification of a receptor tyrosine kinase inhibitor CP-724714 inhibits SADS-CoV related swine diarrhea coronaviruses infection in vitro - The outbreak of the COVID-19 epidemic in 2020 has caused unprecedented panic among all mankind, pointing the major importance of effective treatment. Since the emergence of the swine acute diarrhea syndrome coronavirus (SADS-CoV) at the end of 2017, multiple reports have indicated that the bat-related SADS-CoV possesses a potential threat for cross-species transmission. Vaccines and antiviral drugs development deserve more attention. In this study, we found that the HER2 phosphorylation…
Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate - INTRODUCTION: While there has been considerable progress in the development of vaccines against SARS-CoV-2, largely based on the S (spike) protein of the virus, less progress has been made with vaccines delivering different viral antigens with cross-reactive potential.
The sesquiterpenes with the COVID-19 Mpro inhibitory activity from the Carpesium abrotanoides L - The extract of the whole plant of Carpesium abrotanoides L. yielded four new sesquiterpenes including a novel skeleton (claroguaiane A, 1), two guaianolides (claroguaianes B-C, 2-3), and one eudesmanolide (claroeudesmane A, 4), together with three known sesquiterpenoids (5-7). The structures of the new compounds were elucidated by spectroscopic analysis especially 1D and 2D NMR spectroscopy and HRESIMS data. Additionally, all the isolated compounds were preliminarily evaluated for the inhibitive…
Antimicrobial efficiency of chlorine dioxide and its potential use as anti-SARS-CoV-2 agent: mechanisms of action and interactions with gut microbiota - Chlorine dioxide (ClO2) is a disinfectant gas with strong antifungal, antibacterial, and antiviral activities. Applied on hard non-porous surfaces as an aqueous solution or gas, the ClO2 exerts antimicrobial activity through its interaction and destabilization of cell membrane proteins, as well as through DNA/RNA oxidation, triggering cell death. As for viruses, the ClO2 promotes protein denaturalization mechanisms preventing the union between the human cells and the viral envelope. Currently,…
MicroRNA 205-5p and COVID-19 adverse outcomes: Potential molecular biomarker and regulator of the immune response - Coronavirus disease 2019 (COVID-19) is an acute respiratory infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The uncontrolled systemic inflammatory response, resulting from the release of large amounts of pro-inflammatory cytokines, is the main mechanism behind severe acute respiratory syndrome and multiple organ failure, the two main causes of death in COVID-19. Epigenetic mechanisms, such as gene expression regulation by microRNAs (miRs), may be at the…
Cytokine Storm in Acute Viral Respiratory Injury: Role of Qing-Fei-Pai-Du Decoction in Inhibiting the Infiltration of Neutrophils and Macrophages through TAK1/IKK/NF-[Formula: see text]B Pathway - COVID-19 has posed unprecedented challenges to global public health since its outbreak. The Qing-Fei-Pai-Du decoction (QFPDD), a Chinese herbal formula, is widely used in China to treat COVID-19. It exerts an impressive therapeutic effect by inhibiting the progression from mild to critical disease in the clinic. However, the underlying mechanisms remain obscure. Both SARS-CoV-2 and influenza viruses elicit similar pathological processes. Their severe manifestations, such as acute respiratory…
ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection - SARS-CoV-2 triggered the most severe pandemic of recent times. To enter into a host cell, SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2). However, subsequent studies indicated that other cell membrane receptors may act as virus-binding partners. Among these receptors, the epidermal growth factor receptor (EGFR) was hypothesized not only as a spike protein binder, but also to be activated in response to SARS-CoV-2. In our study, we aim at dissecting EGFR activation and its major…
ACP-Dnnel: anti-coronavirus peptides’ prediction based on deep neural network ensemble learning - The ongoing COVID-19 pandemic has caused dramatic loss of human life. There is an urgent need for safe and efficient anti-coronavirus infection drugs. Anti-coronavirus peptides (ACovPs) can inhibit coronavirus infection. With high-efficiency, low-toxicity, and broad-spectrum inhibitory effects on coronaviruses, they are promising candidates to be developed into a new type of anti-coronavirus drug. Experiment is the traditional way of ACovPs’ identification, which is less efficient and more…
Cell surface nucleocapsid protein expression: A betacoronavirus immunomodulatory strategy - We recently reported that SARS-CoV-2 nucleocapsid (N) protein is abundantly expressed on the surface of both infected and neighboring uninfected cells, where it enables activation of Fc receptor-bearing immune cells with anti-N antibodies (Abs) and inhibits leukocyte chemotaxis by binding chemokines (CHKs). Here, we extend these findings to N from the common cold human coronavirus (HCoV)-OC43, which is also robustly expressed on the surface of infected and noninfected cells by binding heparan…